Company intelligence / Profile preview

Vivance

Ownership: Private
Development stage: Preclinical

Overview

Vivance’s lead product—formerly known as the AWAK PD—is a wearable peritoneal dialysis system that enables patients with end-stage renal disease to perform dialysis on-the-go. The company has completed pre-pivotal human trials in Singapore and plans a pivotal trial in the US starting 2025. Its AI-powered chronic kidney disease progression prediction model received FDA Breakthrough Device Designation in late 2023

Therapeutic areas: Nephrology
Modalities: DeviceDigital health toolArtificial intelligence-based software
Industry: Therapeutic Medical Devices

Partnerships

Singapore General Hospital – clinical trials partner

Beyond the preview

Go deeper on Vivance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivance.

Explore the full profile